- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | CARGO Therapeutics GAAP EPS of -$0.88 | 1 | Seeking Alpha | ||
| CARGO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.11. | Cargo Therapeutics, Inc.: CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity | 1 | GlobeNewswire (USA) | ||
| 11.10. | CARGO Therapeutics (NASDAQ:CRGX) Trading Up 6.2% - Time to Buy? | 1 | MarketBeat | ||
| 28.09. | CARGO Therapeutics (NASDAQ:CRGX) Stock Price Down 6.2% | 3 | MarketBeat | ||
| 20.09. | Cargo Therapeutics CFO Anup Radhakrishnan sells shares worth over $40k | 2 | Investing.com | ||
| 12.09. | Piper Sandler bekräftigt Overweight-Einstufung für Cargo Therapeutics-Aktien | 1 | Investing.com Deutsch | ||
| 17.08. | Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week | 1 | The Motley Fool | ||
| 13.08. | CARGO Therapeutics GAAP EPS of -$1.02 | 1 | Seeking Alpha | ||
| 13.08. | Cargo Therapeutics maintains Buy stock rating amid trial progress | 1 | Investing.com | ||
| 12.08. | CARGO Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | CARGO Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | CARGO Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | CARGO Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 04.06. | CARGO Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Hedge Fund and Insider Trading News: Bill Ackman, Jim Chanos, Daniel Loeb, Mark Yusko, Citadel LLC, CARGO Therapeutics Inc (CRGX), Apple Inc. (AAPL), and More | 5 | Insider Monkey | ||
| 28.05. | CARGO Therapeutics looks to raise $110M through equity financing | 1 | Seeking Alpha | ||
| 28.05. | CARGO Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Cargo Therapeutics, Inc.: CARGO Therapeutics to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 28.05. | Cargo Therapeutics, Inc.: CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing | 1 | GlobeNewswire (USA) | ||
| 21.03. | Cargo Therapeutics, Inc.: CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 305 | GlobeNewswire (Europe) | - Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 - SAN MATEO, Calif.,... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,900 | -0,05 % | Trendwendesignal - Evotec, BioNxt Solutions, Moderna | "Ohne Investition keine Innovation und ohne Innovation kein Fortschritt" sollte das Motto in allen Wirtschaftszweigen der Welt sein. Ob im Maschinenbau, im Automobilbau, der Elektrotechnik wie auch... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis | ||
| QIAGEN | 39,625 | +2,02 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
Das Unternehmen CARGO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 15,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARGO THERAPEUTICS INC finden Sie auf Wallstreet Online.
